Ventyx Biosciences reports Q3 EPS (32c), consensus (45c)

“I am proud of the Ventyx team for achieving two key milestones this year, generating data from the Phase 2a study with our CNS penetrant NLRP3 inhibitor VTX3232 in patients with early Parkinson’s disease and, more recently, data from the VTX3232 Phase 2 study in participants with obesity and cardiovascular risk factors. Key takeaways from the latter study were hsCRP levels were reduced by nearly 80% and, additionally, we saw significant reductions in IL-6, hsCRP, Lp(a) and other markers of systemic inflammation,” said Raju Mohan, Chief Executive Officer. “Earlier in the year, we reported data showing that treatment with VTX3232 yields significant reductions in NLRP3-mediated biomarkers in the plasma and CSF of patients with early Parkinson’s disease. These results position VTX3232 as a next generation, oral therapy, targeting inflammation in cardiovascular, neuroinflammatory and neurodegenerative diseases. We are looking forward to achieving our third major milestone of 2025 by reporting topline data from our Phase 2 study of VTX2735 in recurrent pericarditis during the fourth quarter.”